Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Apr 24, 2026; 17(4): 118070
Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.118070
Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.118070
Three kinds of drug-eluting bead transarterial chemoembolisation for treating patients with unresectable non-small cell lung cancer
Hui-Feng Yuan, Dong-Lin Kuang, De-Chao Jiao, Yong-Hua Bi, Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Dong-Lin Kuang, De-Chao Jiao, Yong-Hua Bi, Minimally Invasive Interventional Ward, Henan Hospital of Beijing Tiantan Hospital, Capital Medical University, Zhengzhou 450052, Henan Province, China
Author contributions: Yuan HF, Kuang DL and Bi YH participated in the conception and design of the study and were involved in the acquisition, analysis, or interpretation of data; Yuan HF, Kuang DL and Jiao DC wrote the manuscript; Bi YH, Yuan HF and Jiao DC accessed and verified the study data; Bi YH revised the manuscript; all authors critically reviewed and provided final approval of the manuscript; all authors were responsible for the decision to submit the manuscript for publication.
Institutional review board statement: This investigation was approved by the Institutional Review Board of the First Affiliated Hospital of Zhengzhou University (No. 2023-KY-1002-002).
Informed consent statement: The need for patient consent was waived due to the retrospective nature of the study.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement:
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Corresponding author: Yong-Hua Bi, MD, PhD, Professor, Department of Interventional Radi
Received: December 23, 2025
Revised: January 25, 2026
Accepted: March 5, 2026
Published online: April 24, 2026
Processing time: 119 Days and 20.1 Hours
Revised: January 25, 2026
Accepted: March 5, 2026
Published online: April 24, 2026
Processing time: 119 Days and 20.1 Hours
Core Tip
Core Tip: This is a retrospective study to investigate the safety, effectiveness and cost-effectiveness of doxorubicin (DOX), oxaliplatin (OXA) and gemcitabine (GEM) drug-eluting bead transarterial chemoembolisation (DEB-TACE) in treating patients with unresectable non-small cell lung cancer (NSCLC). Our study indicates that DOX, OXA and GEM-eluting DEB-TACE may be an effective and safe treatment approach for unresectable NSCLC, with patients in the OXA group pot